Drug Profile
S 7 - Kyorin
Latest Information Update: 10 Nov 2006
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Class Cytostatic antibiotics
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Nov 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 03 Jul 2001 No-Development-Reported Preclinical for Cancer in Japan (Unspecified route)